PMID- 9285931
OWN - NLM
STAT- MEDLINE
DCOM- 19980218
LR  - 20190818
IS  - 0196-9781 (Print)
IS  - 0196-9781 (Linking)
VI  - 18
IP  - 6
DP  - 1997
TI  - Further evidence that the tachykinin PG-KII is a potent agonist at central NK-3, 
      but not NK-1, receptors.
PG  - 825-33
AB  - Intracerebroventricular (i.c.v.) injection of tachykinins (TKs) inhibits ethanol 
      intake and angiotensin II-induced water intake; the effects are apparently 
      mediated by NK-3 and NK-1 receptors, respectively. The present study evaluated 
      the effect of the TK PG-KII, a novel kassinin-like peptide isolated from the skin 
      of the Australian frog Pseudophryne guntheri, in these in vivo tests for central 
      activity. PG-KII, given by i.c.v. injection, potently inhibited alcohol intake in 
      genetically selected alcohol-preferring rats, being about 3 times more potent 
      than the selective NK-3 receptor agonist NH2-SENK. The dose of 100 ng/rat, that 
      markedly inhibited ethanol intake, did not inhibit food intake and prandial 
      drinking in food deprived rats, providing evidence that the effect of PG-KII on 
      ethanol intake is behaviorally selective. The effect on ethanol intake was 
      inhibited by i.c.v. injection of the NK-3 receptor antagonist R820, but was not 
      modified by the NK-1 receptor antagonist SR 140333. PG-KII inhibited drinking 
      induced by angiotensin II only at doses of 300 or 1000 ng/rat, being about 5 
      times less potent than the selective NK-1 receptor agonist [Sar9, Met(O2)11] 
      substance P. These doses of PG-KII produced also marked increase in competing 
      behaviors, such as grooming and locomotion. The dose of 1000 ng/rat evoked a 
      general inhibition of the ingestive behavior, reducing also food intake. The 
      i.c.v. injection of the NK-1 receptor antagonist SR 140,333 only slightly 
      inhibited the effect of PG-KII on angiotensin II-induced drinking, while it 
      markedly reduced that of [Sar9, Met(O2)11] substance P. These findings, in 
      accordance with those of previous studies, indicate that PG-KII is endowed with 
      marked activity at central NK-3 receptors, and low activity at NK-1 receptors.
FAU - Polidori, C
AU  - Polidori C
AD  - Department of Pharmacological sciences and Experimental Medicine, University of 
      Camerino, Italy. polidori@cambio.unicam.it
FAU - Panocka, I
AU  - Panocka I
FAU - Ciccocioppo, R
AU  - Ciccocioppo R
FAU - Broccardo, M
AU  - Broccardo M
FAU - Improta, G
AU  - Improta G
FAU - Regoli, D
AU  - Regoli D
FAU - Massi, M
AU  - Massi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Peptides
JT  - Peptides
JID - 8008690
RN  - 0 (Neurokinin-1 Receptor Antagonists)
RN  - 0 (PG-KII peptide)
RN  - 0 (Piperidines)
RN  - 0 (Quinuclidines)
RN  - 0 (Receptors, Neurokinin-2)
RN  - 0 (Receptors, Neurokinin-3)
RN  - 0 (Tachykinins)
RN  - 11128-99-7 (Angiotensin II)
RN  - 153050-21-6 (SR 140333)
RN  - SZB83O1W42 (Pyrrolidonecarboxylic Acid)
SB  - IM
MH  - Alcohol Drinking
MH  - Angiotensin II/pharmacology
MH  - Animals
MH  - Brain/*drug effects
MH  - Drinking/drug effects
MH  - Eating/drug effects
MH  - Injections, Intraventricular
MH  - Male
MH  - Neurokinin-1 Receptor Antagonists
MH  - Piperidines/pharmacology
MH  - Pyrrolidonecarboxylic Acid/analogs & derivatives
MH  - Quinuclidines/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Neurokinin-2/*agonists
MH  - Receptors, Neurokinin-3/*agonists
MH  - Stereoisomerism
MH  - Tachykinins/administration & dosage/*pharmacology
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - S0196-9781(97)00022-3 [pii]
AID - 10.1016/s0196-9781(97)00022-3 [doi]
PST - ppublish
SO  - Peptides. 1997;18(6):825-33. doi: 10.1016/s0196-9781(97)00022-3.